Ticagrelor
| File:Ticagrelor structure.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
(1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol | |
| Clinical data | |
| Routes of administration | oral |
| Identifiers | |
| CAS Number | 274693-27-5 |
| ATC code | none |
| PubChem | CID 9871419 |
| Synonyms | AZD6140 |
| Chemical data | |
| Formula | C23H28F2N6O4S |
| Molar mass | 522.567 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Ticagrelor (trade name Brilinta) is a platelet aggregation inhibitor produced by AstraZeneca. The PLATO clinical trial, funded by AstraZeneca, in mid-2009 found that ticagrelor had better mortality rates than clopidogrel (9.8% vs. 11.7%, p<0.001) in treating patients with acute coronary syndrome. Patients given ticagrelor were less likely to die from vascular causes, heart attack, or stroke but had slightly greater chances of major bleeding which was non-significant (11.6 vs. 11.2, p=0.4).[1]
Mechanism of action
Like prasugrel, clopidogrel and ticlopidine, ticagrelor blocks ADP receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, the blockage is reversible. Moreover, it does not need hepatic activation, which could reduce the risk of drug interactions.[2][3]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />| 40px | This drug article relating to the blood and blood forming organs is a stub. You can help ssf by expanding it. |
- ↑ Wallentin, Lars; Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Held, C; Horrow, J; Husted, S; James, S (August 30, 2009). "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes". NEJM. 361 (11): 1045–57. doi:10.1056/NEJMoa0904327. PMID 19717846.
- ↑ H. Spreitzer (February 4, 2008). "Neue Wirkstoffe - AZD6140". Österreichische Apothekerzeitung (in German) (3/2008): 135.
- ↑ Owen, RT, Serradell, N, Bolos, J (2007). "AZD6140". Drugs of the Future. 32 (10): 845–853. doi:10.1358/dof.2007.032.10.1133832.
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- ADP receptor inhibitors
- Triazolopyrimidines
- Organofluorides
- Alcohols
- Blood and blood forming organ drug stubs
- 2Fix
- CS1 maint: Unrecognized language
- CS1 maint: Multiple names: authors list
